Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair
Abstract
By applying our pioneering “Targeted Drug Conjugate (TDC)” concept, a new PARP1-specific Pt(II)-based TDC for the treatment of ovarian cancer was reported. In vitro biological assays indicated that the representative compound Ola-604 could target PARP1, exhibit an inhibitory effect on SKOV3 cancer cells, and overcome cisplatin resistance via inducing cell apoptosis, causing cell cycle arrest, enhancing the cellular accumulation of platinum element, promoting the level of DNA platination within the genome, and suppressing DNA damage repair. Notably, compound Ola-604 demonstrated higher tumor growth inhibitory efficacy than cisplatin, olaparib, and their physical mixture in SKOV3 mice xenograft models, while exhibiting lower toxicity. Overall, the TDC entity sets a new benchmark for precision therapy in ovarian cancer.
Fields of Study & Subjects
PARP inhibition in cancer therapy
Metal complexes synthesis and properties
Cancer Mechanisms and Therapy
Publication details
- Journal / source
- Inorganic Chemistry
- Publisher
- American Chemical Society (ACS)
- Volume
- 65
- Issue
- 17
- Pages
- 9577–9590
- Publication date
- 17 April 2026
- Language
- EN